Atherogenic dyslipidemia and oxidative stress: a new look

Translational Research

Volumn 153, Issue 5, 2009, Pages 217-223

  Rizzo, Manfredi ^a   Kotur Stevuljevic, Jelena ^b   Berneis, Kaspar ^c   Spinas, Giatgen ^c   Rini, Giovam Battista ^a   Jelic Ivanovic, Zorana ^b   Spasojevic Kalimanovska, Vesna ^b   Vekic, Jelena ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Faculty of Pharmacy   (Serbia)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 64349105661     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.01.008     Document Type: Review

References (93)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
2. Berneis K.K., and Krauss R.M. Metabolic origin and clinical significance of LDL heterogeneity. Lipid Res 43 (2002) 1363-1379
3. Galeano N.F., Al-Haideri M., Keyserman F., Rumsey S.C., and Deckelbaum R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39 (1998) 1263-1273
4. Tribble D.L., Krauss R.M., Lamberg M.G., and Thiel P.M. van den Berg JM. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res 36 (1995) 662-671
5. Albertini R., Moratti R., and De Luca G. Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies. Curr Mol Med 2 (2002) 579-592
6. Matsuura E., Hughes G.R., and Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 7 (2008) 558-566
7. Dalle-Donne I., Rossi R., Colombo R., Giustarini D., and Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 52 (2006) 602-623
8. Tarpey M.M., Wink D.A., and Grisham M.B. Methods for detection of reactive metabolities of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 286 (2004) 431-444
9. Montuschi P., Bernes P.J., and Roberts L.J. Isoprostanes: markers and mediators of oxidative stress. FASEB J 18 (2004) 1791-1800
10. Uchida K. Histidine and lysine as targets of oxidative modification. Amino Acids 25 (2003) 249-257
11. Clempus R.E., and Griendling K.K. Reactive oxygen species signalling in vascular smooth muscle cells. Cardiovas Res 71 (2006) 216-225
12. Griendling K.K., Sorescu D., and Ushio-Fukai M. NADPH oxidase: role in cardiovascular biology and disease. Circ Res 86 (2000) 494-501
13. Spiekermann S., Landmesser U., Dikalov S., et al. Electron spin resonance characterisation of vascular xanthine and NADPH oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107 (2003) 1383-1389
14. Alp N.J., and Channon K.M. Regulation of endothelial nitric oxide nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscl Thromb Vasc Biol 24 (2004) 413-420
15. Mueller C.F.H., Laude K., McNally S.J., and Harrison D.G. Redox mechanisms in blood vessels. Arterioscl Thromb Vasc Biol 25 (2005) 274-278
16. Babior B.M., Lambeth J.D., and Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys 397 (2002) 342-344
17. Lamberth J.D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4 (2004) 181-189
18. Guzik T., and Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 11 (2006) 524-533
19. Channon K.M., and Guzik T.J. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 53 (2002) 515-524
20. Kaminski P.M., and Wolin M.S. Hypoxia increases superoxide anion production from bovine coronary microvessels, but not cardiac myocytes, via increased xanthine oxidase. Microcirculation 1 (1994) 231-236
21. McNally J.S., Davis M.E., Giddens D.P., et al. Role of xanthine oxidoreductase and NADPH oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285 (2003) 2290-2297
22. Landmesser U., Dikalov S., Price S.R., et al. Oxydation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111 (2003) 1201-1209
23. Turrens J.F. Mitochondrial formation of reactive oxygen species. J Physiol 552 (2003) 335-344
24. Griendling K.K., and Fitzgerald G.A. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108 (2003) 1912-1916
25. Harrison D.G. Endothelial function and oxidant stress. Clin Cardiol 20 (1997) 11-17
26. Jung H.H., Choi D.H., and Lee S.H. Serum malondialdehyde and coronary artery disease in hemodialisis patients. Am J Nephrol 24 (2004) 537-542
27. Bridges A.B., Scott N.A., Pringle T.H., McNeill G.P., and Belch J. Relationship between the extent of coronary artery disease and indicators of free radical activity. Clin Cardiol 15 (1992) 169-174
28. Wang X.L., Adachi T., Sim A.S., and Wilcken D.E.I. Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Arterioscler Thromb Vasc Biol 18 (1998) 1915-1921
29. Akkus I., Saglam N.I., Caglayam O., Vural A., Kalan S., and Saglam M. Investigation of erythrocyte membrane lipid peroxidation and antioxidant defense systems of patients with coronary artery disease (CAD) documented by angiography. Clin Chim Acta 244 (1996) 173-180
30. Landmesser U., Merten R., Spiekermann S., Buttner K., Drexler H., and Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 101 (2000) 2264-2270
31. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91 (1993) 2546-2551
32. Kotur-Stevuljevic J., Memon L., Stefanovic A., et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 40 (2007) 181-187
33. Mahapatra S., Padhiary K., Mishra T., Nayak N., and Satpathy M. Study on body mass index, lipid profile and lipid peroxidation status in coronary artery disease. J Indian Med Assoc 96 (1998) 39-40
34. Rankinen T., Hietanen E., Väisänen S., et al. Relationship between lipid peroxidation and plasma fibrinogen in middle-aged men. Thromb Res 99 (2000) 453-459
35. Memon L., Spasojević-Kalimanovska V., Bogavac-Stanojević N., et al. Association of C-reactive protein and fibrinogen with the presence and extent of angiographically verified coronary artery disease. Tohoku J Exp Med 209 (2006) 197-206
36. Griffin B.A., Caslake M.J., Yip B., Tait G.W., Packard C.J., and Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83 (1990) 59-67
37. Rizzo M., and Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment QJM. Int J Med 99 (2006) 1-14
38. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
39. Rizzo M., and Berneis K. Who needs to care about small, dense low density lipoproteins?. Int J Clin Pract 61 (2007) 1949-1956
40. Rizzo M., Rini G.B., Spinas G., and Berneis K. A practical method to determine the "atherogenic lipoprotein phenotype.". Arch Med Sci 4 (2008) 215-218
41. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 150 (2005) 859-870
42. Grundy S.M., Cleeman J.I., Daniels S.R., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
43. Rizzo M., and Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 23 (2007) 14-20
44. Sattar N., Petrie J.R., and Jaap A.J. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 138 (1998) 229-235
45. Superko H.R. Beyond LDL cholesterol reduction. Circulation 94 (1996) 2351-2354
46. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002) 3143-3421
47. Packard C.J. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 17 (2006) 412-417
48. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., and Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7 (2007) 53-72
49. Sacks F.M., and Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocr Metab 88 (2003) 4525-4532
50. Lamarche B., Lemieux I., and Després J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25 (1999) 199-211
51. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 (2004) 1496-1504
52. Landray M.J., Sagar G., Muskin J., Murray S., Holder R.L., and Lip G.Y.H. Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. Q J Med 91 (1998) 345-351
53. Skoglund-Andersson C., Tang R., Bond M.G., de Faire U., Hamsten A., and Karpe F. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 19 (1999) 2422-2430
54. Bokemark L., Wikstrand J., Attvall S., Hulthe J., Wedel H., and Fagerberg B. Insulin resistance and intima-media thickness in the carotid and femoral arteries of clinically healthy 58-year-old men. The Atherosclerosis and Insulin Resistance Study (AIR). J Intern Med 249 (2001) 59-67
55. Hallman D.M., Brown S.A., Ballantyne C.M., Sharrett A.R., and Boerwinkle E. Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study. Biomarkers 9 (2004) 190-202
56. Liu M.L., Ylitalo K., Nuotio I., Salonen R., Salonen J.T., and Taskinen M.R. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 33 (2002) 1255-1260
57. Watanabe T., Koba S., Kawamura M., et al. Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. Metabolism 53 (2004) 476-482
58. Berneis K., Jeanneret C., Muser J., Felix B., and Miserez A.R. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 54 (2005) 227-234
59. van Tits L.J., Smilde T.J., van Wissen S., de Graaf J., Kastelein J.J., and Stalenhoef A.F. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 52 (2004) 177-184
60. Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., and Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35 (2004) 2248-2252
61. Rizzo M., Krayenbühl P.A., Pernice V., Frasheri A., Rini G.B., and Berneis K. LDL size and subclasses in patients with abdominal aortic aneurysm. Int J Cardiol (2009) In press
62. Rizzo M., Pernice V., Frasheri A., and Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis 197 (2008) 237-241
63. O'Neal D.N., Lewicki J., Ansari M.Z., Matthews P.G., and Best J.D. Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects. Atherosclerosis 136 (1998) 1-8
64. Berneis K., Rizzo M., Fruzzetti F., Lazzaroni V., and Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 186-189
65. Rizzo M., Trepp R., Berneis K., and Christ E.R. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocr 156 (2007) 361-367
66. Rizzo M., Berneis K., Altinova A.E., et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. Diabetic Med 25 (2008) 1406-1411
67. Haffner S.M., Mykkanen L., Robbins D., et al. A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 38 (1995) 1328-1336
68. Aeberli I., Zimmermann M.B., Molinari L., Lehmann R., l'Allemand D., Spinas G.A., and Berneis K. Fructose intake is a predictor of LDL particle size in overweight schoolchildren. Am J Clin Nutr 86 (2007) 1174-1178
69. Krayenbuehl P.A., Wiesli P., Schmid C., Lehmann R., Spinas G.A., and Berneis K. Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size. Swiss Med Wkly 138 (2008) 275-280
70. Gazi I., Tsimihodimos V., Filippatos T., Bairaktari E., Tselepis A.D., and Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 55 (2006) 885-891
71. Julius U., Dittrich M., and Pietzsch J. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int J Clin Pract 61 (2007) 1798-1804
72. Gentile M., Panico S., Jossa F., et al. Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. Clin Chim Acta 388 (2008) 179-183
73. Rizzo M., Pernice V., Frasheri A., et al. Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocr (2009) In press
74. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
75. Barter P. Options for therapeutic intervention: how effective are the different agents?. Eur Heart J Suppl 8 (2006) F47-F53
76. Vekic J., Kotur-Stevuljevic J., Jelic-Ivanovic Z., et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37 (2007) 715-723
77. Vekic J., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V., Memon L., et al. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis (2008) 10.1016/j.atherosclerosis.2008.05.047
78. Kutuk O., and Basaga H. Inflammation meets oxidation: NF-κB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 912 (2003) 549-557
79. Tribble D.L., Rizzo M., Chait A., Lewis D.M., Blanche P.J., and Krauss R.M. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small dense low-density lipoproteins. Am J Med 110 (2001) 103-110
80. Zhang R., Brennan M.L., Shen Z., et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277 (2002) 46116-46122
81. Cyrus T., Pratico D., Zhao L., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2277-2282
82. Sorescu D., Szocs K., and Griendling K.K. NAD(P)H oxidases and their relevance to atherosclerosis. Trends Cardiovasc Med 11 (2001) 124-131
83. Cominacini L., Garbin U., Pasini A.F., et al. Antioxidans inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 22 (1997) 117-127
84. Ishii H., Kizaki K., Horie S., and Kazama M. Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes. J Biol Chem 271 (1996) 8458-8465
85. Heermeier K., Leicht W., Palmetshofer A., Ullrich M., Wanner C., and Galle J. Oxidized LDL suppresses NF-kappaB and overcomes protection from apoptosis in activated endothelial cells. J Am Soc Nephrol 12 (2001) 456-463
86. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2243-2247
87. Inoue T., Uchida T., Kamishirado H., Takayanagi K., Hayashi T., and Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 37 (2001) 775-779
88. Miyazaki T., Shimada K., Sato O., et al. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis 179 (2005) 139-145
89. Yamashita H., Ehara S., Yoshiyama M., et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J 71 (2007) 681-687
90. Hulthe J., and Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 22 (2002) 1162-1167
91. Meisinger C., Baumert J., Khuseyinova N., Loewel H., and Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112 (2005) 651-657
92. Ishigaki Y., Katagiri H., Gao J., et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118 (2008) 75-83
93. Katsiki N., and Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis?. Clin Nutr (2009) In press